Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®

Vernon K. Sondak*, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations

Abstract

The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine® is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX®. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine® in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalSeminars in Cancer Biology
Volume13
Issue number6
DOIs
StatePublished - Dec 2003

Keywords

  • Adjuvant therapy
  • Cancer vaccines
  • HLA antigens
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®'. Together they form a unique fingerprint.

Cite this